TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04682171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: * Gallium aluminium arsenide laser device will be used with wavelength of 850nm, power 100 mW, spot size of 1.0 mm and energy of 6J/point for 60seconds. Total 8 points will be irradiated. It will take 20 minutes.~* Patient will receive treatment in supine position with the affected knee(s) slightly flexed supported by the pillow or rolled towel.~* On the affected knee the laser probe will placed with full contact with skin at 8 points. Three points at medial side of the knee, three points at lateral side and two points at the medial edge of the bicep femoris muscle tendon and semitendinosus muscle tendon in the popliteal fossa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise Therapy
Description: 1. Quadriceps isometric strengthening exercises.~2. Range of motion and active stretching exercises applied to hamstring and quadriceps muscle.~3. Hamstring muscle isometric exercises~4. Active ankle pump.~5. Short arc terminal extension exercises for the knee joint.~6. Static and dynamic strengthening exercises for the hip abductors, adductors and extensor group of muscles.~7. Non-weight bearing progressive resistance exercises with weighted cuffs, with progression to closed chain exercises as patient's pain allows.~8. Isometric exercises were applied with 6 second contractions and rest period of 2 seconds. Isotonic exercises were started as 10 repetitions with half of weight of 10 RM, 10 repetitions with three fourth of this weight and 10 repetitions with whole 10 RM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercise Therapy
Description: 1. Quadriceps isometric strengthening exercises.~2. Range of motion and active stretching exercises applied to hamstring and quadriceps muscle.~3. Hamstring muscle isometric exercises~4. Active ankle pump.~5. Short arc terminal extension exercises for the knee joint.~6. Static and dynamic strengthening exercises for the hip abductors, adductors and extensor group of muscles.~7. Non-weight bearing progressive resistance exercises with weighted cuffs, with progression to closed chain exercises as patient's pain allows.~8. Isometric exercises were applied with 6 second contractions and rest period of 2 seconds. Isotonic exercises were started as 10 repetitions with half of weight of 10 RM, 10 repetitions with three fourth of this weight and 10 repetitions with whole 10 RM
Study: NCT00649090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: Exemestane 25 mg oral tablet once daily for a maximum of 3 years
Study: NCT02720536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
Study: NCT04750174

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesiotape (KT) has been used by Dr. Kenzo Kase for the first time as based on the opinion that more successful results can be obtained in a banding method similar to the structural characteristics and flexibility of human skin without limiting the joint movements for edema control, joint protection, and proprioception training. In recent years, KT have been applied with a wide variety of techniques including muscle techniques for the inhibition and stimulation of muscles, fascia correction technique which aims to reduce tension and adhesions by making vibration movement between the fascia layers and field correction technique aiming to reduce regional pressure in the presence of pain, inflammation or edema as well as lymphatic correction technique for regulating lymphatic circulation .

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesiotape (KT) has been used by Dr. Kenzo Kase for the first time as based on the opinion that more successful results can be obtained in a banding method similar to the structural characteristics and flexibility of human skin without limiting the joint movements for edema control, joint protection, and proprioception training. In recent years, KT have been applied with a wide variety of techniques including muscle techniques for the inhibition and stimulation of muscles, fascia correction technique which aims to reduce tension and adhesions by making vibration movement between the fascia layers and field correction technique aiming to reduce regional pressure in the presence of pain, inflammation or edema as well as lymphatic correction technique for regulating lymphatic circulation .
Study: NCT00985166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)
Description: A Single 0.5 mL subcutaneous injection at Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: M-M-R II
Description: A Single 0.5 mL subcutaneous injection at Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: M-M-R II
Description: A Single 0.5 mL subcutaneous injection at Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Varivax
Description: A Single 0.5 mL subcutaneous injection at Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: A Single 0.5 mL subcutaneous placebo injection at Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo
Description: A Single 0.5 mL subcutaneous placebo injection at Day 1
Study: NCT02839837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise will be performed on a stationary cycle ergometer for 15 minutes at an intensity of 35% heart rate reserve or 70% heart rate reserve. During the control condition the participant will remain seated on the stationary cycle for 15 minutes and will not perform exercise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired Associative Stimulation
Description: After aerobic exercise participants will receive a paired associative stimulation (PAS) paradigm. PAS consists of paired brain and peripheral nerve stimuli. Participants will receive 200 paired stimuli. Peripheral nerve stimulation will be delivered to the median nerve at the level of the wrist via electrical stimulation at 300% perceptual threshold. Brain stimulation will be delivered via transcranial magnetic stimulation (TMS) over the hand knob of the motor cortex at an intensity that elicits a 1mV response in the contralateral abductor pollicis brevis muscle. During each paired stimulation, peripheral nerve stimulation will precede the TMS stimulation by 25ms.
Study: NCT02800226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10Hz
Description: Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS
Description: Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
Study: NCT04962802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manhood 2.0
Description: Manhood 2.0 engages young men in questioning, challenging, and transforming harmful gender norms, with the goal of reducing intimate partner and sexual violence and unintended teen pregnancy. Manhood 2.0 is a male-only group-level intervention, based on social cognitive theory, social norm theory, theory of gender and power, and the theory of reasoned action. Activities include group discussion, role playing, knowledge sharing, and skill-building; their purpose is to challenge young men to think critically about social expectations and restrictive norms, engage in dialogue about these gender norms, and then assess the way rigid norms affect their attitudes and behaviors toward key issues, including intimate relationships, gender-based violence, substance abuse, sexually transmitted infections, and early pregnancy. Sessions are two hours long and occur once a week for seven weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Post-High School Readiness
Description: Post-High School Readiness program helps young men prepare for life after high school. This includes helping them prepare resumes, learning how to apply to jobs or colleges, providing interview prep, and other life skills. It is a male-only group-level program that includes discussion, feedback, knowledge sharing, and skill-building; their purpose is to prepare young men for life after high school. Sessions are two hours long and occur once a week for seven weeks.
Study: NCT02057120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: Application of Kinesio (Kinesio Tex Gold ®) of black color. The tape will be applied from proximal to distal, leaving the anterosuperior iliac spine Bottom, passing over the Rectus Femoris and ending in the region of the anterior tibia tuberosity with a voltage of 25 %.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio Taping placebo
Description: The volunteer who is allocated at random in the placebo group will receive an application of Kinesio transverse way the rectus femoris muscle, in order to verify a possible placebo effect of application of tape.
Study: NCT02705144

Intervention type: OTHER
Intervention: analysis of the number of stem cell niches
Description: to assess stem cell compartments in their niches and their proliferative and developmental properties in vitro

Intervention type: OTHER
Intervention: analysis of the number of stem cell niches
Description: to assess stem cell compartments in their niches and their proliferative and developmental properties in vitro

Intervention type: OTHER
Intervention: analysis of the number of stem cell niches
Description: to assess stem cell compartments in their niches and their proliferative and developmental properties in vitro
Study: NCT01800266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervision Practices of TF-CBT
Description: Supervisors will be trained in one of two supervision strategies: Symptom and Fidelity Monitoring (SFM) or Symptom and Fidelity Monitoring + Behavioral Rehearsal (SFM + BR)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervision Practices of TF-CBT
Description: Supervisors will be trained in one of two supervision strategies: Symptom and Fidelity Monitoring (SFM) or Symptom and Fidelity Monitoring + Behavioral Rehearsal (SFM + BR)
Study: NCT02086266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILATES

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT and AES
Study: NCT03457207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined minilaparotomy- laparoscopy approach
Description: Laparoscopic aspiration of cyst then guided its extracorporeal cystectomy then reposition and evaluation by laproscopy
Study: NCT02285426

Intervention type: DEVICE
Intervention: Pentax EB-1990i HD-bronchoscope guided biopsy
Description: 3 different types of bronchoscopy image settings will be used investigating the entire bronchial tree.~When sites with abnormal or suspicious vascular patterns are detected meeting the criteria of abnormality \[visual scale adapted from Herth 2009 and Zaric 2013\] the investigator will change to a normal bronchoscope and take biopsies from each site and a biopsy from a normal secondary carina on the contralateral site as control.
Study: NCT03645057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole
Description: This topical ointment is FDA-approved to treat atopic dermatitis of moderate or less severity in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus 0.03% Ointment
Description: This topical ointment is FDA-approved to treat atopic dermatitis in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
Study: NCT05335720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhEGF
Description: EASYEF® spray 50 mcg, sprayed twice a day for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhEGF
Description: EASYEF® spray 50 mcg, sprayed twice a day for 14 days.
Study: NCT02924974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: mixed with bupivacaine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lidocaine
Description: sham procedure (s.c. lidocaïne)
Study: NCT01141738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Problem-Solving Intervention
Description: Subjects will meet for two counseling sessions while their family member is hospitalized and will receive the treatment manual, which contains the content for the 10 sessions, work sheets, and handouts. The standardized content will be complemented by tailoring to the specific concerns and problems of CGs which are influenced by culture and developmental life stage as well as the stroke and other environmental and personal factors. Problems specific to stroke caregiving are emphasized. After the stroke survivor has been discharged, the counselor will contact the CG weekly by phone for 5 weeks and then bi-weekly for the next three sessions (a total of 10 sessions) at times convenient for the CG.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait List Control
Description: Subjects in the WLC condition will receive usual patient and family education. If these subjects are noted to be distressed when assessment measures are administered or during conversation, the research assistant (RA) will inform the PI or Co-PI, who will follow-up. To aid retention, a counselor who is naïve to the CPSI will call the WLC subjects in the second and fifth months post-discharge to check contact information and ask how they are doing. Access to individual or group therapy through community resources during this study will be monitored during routine data collection. Following the T3 assessment, the WLC subjects will be offered a minimal intervention (receipt of the Adapting to Stress booklet 100 and five 30 minute telephone sessions).
Study: NCT03646656

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: reciprocal peer support and non reciprocal coach support
Description: Peers and peer coaches provide mutual or one-way support to initiate and sustain behavioral improvements for cardiovascular health, with additional education from study staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reciprocal peer support and non reciprocal coach support
Description: Peers and peer coaches provide mutual or one-way support to initiate and sustain behavioral improvements for cardiovascular health, with additional education from study staff.
Study: NCT01001923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475/SAR164877
Description: Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for REGN475/SAR164877)
Description: Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes
Study: NCT04344600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon lambda alfa-1a subcutaneous injection
Description: Peginterferon lambda-1a 180 micrograms by subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline subcutaneous injection
Study: NCT00696982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: sitagliptin 100 mg once daily for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glibenclamide
Description: glibenclamide 5 mg once a day titrated as neede up to 20 mg a day
Study: NCT00656123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Colon GVAX
Description: Dose escalation: 1.4x10\^8 to 7x10\^8 cells administered in up to 15 intradermal injections on Day 2 of Cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 200 mg/m\^2 administered IV on Day 1 of Cycles 1-4
Study: NCT05048420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: ACL reconstruction and RAMP lesion repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: ACL reconstruction and RAMP lesion repair
Study: NCT04656509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-s sprint inertial load training
Description: A program employing 30 bouts of 4s inertial load sprint training with progressively reduced recovery time (30 to 15 s) between sprints is effective for improving blood volume, VO2peak and maximal power.
Study: NCT04050462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks
Description: Nivolumab 240 mg IV plus Cabiralizumab 4 mg/kg IV every 2 weeks combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks
Description: Nivolumab 240 mg IV plus BMS-986253 1200mg IV every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab 240 mg IV every 2 weeks
Description: Arm 1 (control) Nivolumab 240mg IV every 2 weeks monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg IV every 2 weeks
Description: Arm 1 (control) Nivolumab 240mg IV every 2 weeks monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg IV every 2 weeks
Description: Arm 1 (control) Nivolumab 240mg IV every 2 weeks monotherapy
Study: NCT04218955

Intervention type: COMBINATION_PRODUCT
Intervention: Silver Diamine Flouride
Description: Material used to arrest caries in children
Study: NCT01244243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand & Wrist Assisting Robotic Device
Description: Treatment occurs in 2 hour sessions, 4 times a week over 3 weeks. In each treatment session, you will sit in a chair and have your weak hand attached to a mechanical device (the robot), which will help you open and close your hand. During the treatment, different types of objects (with varying shapes, sizes, and weight) will be placed into your hand. You will be given a variety of instructions related to the grasping, feeling, or identifying of the object in your hand. Sometimes these instructions will be given from the investigator and sometimes from the computer. You will often be asked to grasp, or release, each of these objects as best you can. You will also be asked to concentrate on the object in your hand. An example of what you may be asked to do is to name the object. During other times, you will play games, using the robot to control game parts on the computer screen. At other times, you will move your hand so that the robot can measure your hand function.
Study: NCT03507374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alirocumab
Description: Alirocumab is approved by the FDA as a secondary treatment for high cholesterol for adults whose cholesterol can not be controlled by diet and/or statin treatment. Additionally, Alirocumab works to inhibit the PCSK9 protein.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered subcutaneously every 2 weeks identical to active drug (alirocumab)
Study: NCT01215422

Intervention type: PROCEDURE
Intervention: timed intubation
Description: timed intubation

Intervention type: PROCEDURE
Intervention: timed intubation
Description: timed intubation
Study: NCT00261768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital noise reduction
Study: NCT03330457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (bolus)
Description: fXa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (bolus)
Description: fXa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (bolus)
Description: fXa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (bolus)
Description: fXa inhibitor antidote

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban 80 mg PO QD
Description: fXa inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban 80 mg PO QD
Description: fXa inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban 80 mg PO QD
Description: fXa inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban 80 mg PO QD
Description: fXa inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (infusion IV)
Description: fXa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (infusion IV)
Description: fXa inhibitor antidote

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (infusion IV)
Description: fXa inhibitor antidote
Study: NCT04183972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound examination
Description: the participants will be placed in the supine position, with head turned slightly away from the operating side and arms beside the body. The operator will identify right and left interscalene brachial plexuses by ultrasound equipment (Sonosite EDGE or GE LOGIQ e). Clear images and videos of brachial plexus will be captured and saved.
Study: NCT02715167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide novolizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00122928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Healthy Choices in vending machines; Healthy Choices in cafeteria; Catering (Healthy Choices in site meetings, shutdowns, OT meals, etc.); Targeted Messages: Nutrition; Site Based Rewards and Recognition - Individual Employees Weight Management Tracking Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Healthy Choices in vending machines; Healthy Choices in cafeteria; Catering (Healthy Choices in site meetings, shutdowns, OT meals, etc.); Targeted Messages: Nutrition; Site Based Rewards and Recognition - Individual Employees Weight Management Tracking Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking Paths/Routes; Weight Management Tracking Program; Targeted Messages: Physical Activity; Site Based Rewards and Recognition - Individual Employees

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking Paths/Routes; Weight Management Tracking Program; Targeted Messages: Physical Activity; Site Based Rewards and Recognition - Individual Employees

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental Obesity Program - Healthy Culture
Description: Site Goal Setting; Work Group Alignment to Site Goals; Reporting to Senior Leadership; Leadership Training; Site Leadership, Cross Discipline Teams, Work Groups, Healthy Culture Focal Point Rewards and Recognition